Select Medical closes its sale to a consortium led by Ortenzio, Jackson and WCAS for $16.50 per share, valuing the company at about $3.9 billion. The merger closes July 1, 2026, after stockholders approved on June 26, 2026, and the stock will be delisted on completion. Near-term investors should expect the stock to move toward the offer price with limited post-close upside.
The offer delivers an explicit premium to pre-announcement levels and VWAP, with near-term price convergence to $16.50; delisting implies no further upside beyond the deal value.
SEM will converge to $16.50 on close with minimal further upside after delisting.
Category: M&A. The article reports a completed take-private deal, reshaping SEM from a public healthcare services issuer to a privately held entity with a new controlling sponsor.